Search
Lymphoma, Diffuse
go.drugbank.com/conditions/DBCOND0036855Synonyms: Non-Hodgkin lymphoma, no ICD-O subtype, Non-Hodgkin lymphoma, no ICD-O subtype (morphologic abnormality)Cholesteryl ester transfer protein
go.drugbank.com/bio_entities/BE0003516TargetHumansInvolved in the transfer of neutral lipids, including cholesteryl ester and triglyceride, among lipoprotein particles. Allows the net movement of cholesteryl ester from high density lipoproteins/HDL to triglyceride-rich very low density ...
Synonyms: Lipid transfer protein IFenproporex
go.drugbank.com/drugs/DB01550ApprovedIllicitWithdrawnIn 2006 and 2009, the FDA issued warnings that it had been detected in diet pills sold online, and imported from foreign manufacturers. … It is listed as an illicit substance in many countries due to addiction issues and listed as a prohibited substance by the World Anti-Doping Agency.
International brands: Desobesi-MProducts: IFA-DIETY A. P.Noncanonical Wnt/Ca2+ signaling
smpdb.ca/view/SMP0468891SignalingThe Wnt/Ca²⁺ pathway is activated by the binding of the Wnt ligand to a Frizzled receptor.
3-dehydroquinate dehydratase
go.drugbank.com/bio_entities/BE0001819TargetSalmonella typhiInvolved in the third step of the chorismate pathway, which leads to the biosynthesis of aromatic amino acids. Catalyzes the cis-dehydration of 3-dehydroquinate (DHQ) and introduces the first double bond of the aromatic ring to yield 3-d...
Synonyms: Type I DHQase, Type I dehydroquinaseImatinib
go.drugbank.com/drugs/DB00619ApprovedInvestigationalThe discovery of imatinib also established a new group of therapy called "targeted therapy", since treatment can be tailored specifically to the unique cancer genetics of each patient. … [L42220] Imatinib was approved on February 1st ,2001 by the FDA and November 7th, 2001 by the EMA; however, its European approval has been withdrawn in October 2023.[A263036,L49746,L49751]
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesSynonyms: α-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-toluidideAcute Non-Lymphocytic Leukemia
go.drugbank.com/conditions/DBCOND0038781Drugs: TioguanineSynonyms: Acute myeloid leukemia, no ICD-O subtype (morphologic abnormality), Acute myeloid leukemia, no International Classification of Diseases for Oncology subtypeCutaneous Melanoma
go.drugbank.com/conditions/DBCOND0040978Drugs: IpilimumabSynonyms: Malignant melanoma, no ICD-O subtype, Malignant melanoma, no International Classification of Diseases for Oncology subtypeMelanoma
go.drugbank.com/conditions/DBCOND0020306Synonyms: Malignant melanoma, no ICD-O subtype, Malignant melanoma, no International Classification of Diseases for Oncology subtypeIsocarboxazid
go.drugbank.com/drugs/DB01247Approved[T115] It was first introduced by Roche pharmaceuticals, further developed by Validus pharms Inc and first FDA approved as a prescription drug on July 1st, 1959. … Isocarboxazid has the formula 1-benzyl-2-(5-methyl-3-isoxazolylcarbonyl)hydrazine-isocarboxazid. It is a monoamine oxidase inhibitor.
Categories: Monoamine Oxidase Inhibitors, Non-Selective, Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates